ArticleNPJ breast cancer2023
Evaluation of multigene assays as predictors for response to neoadjuvant chemotherapy in early-stage breast cancer patients.
Article in NPJ breast cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- A Simple and Robust MRI Radiomics Feature for Predicting Pathological Complete Response: A Proof-of-Concept Study in Breast Cancer Neoadjuvant Chemotherapy.Cancer reports (Hoboken, N.J.) · 2026Article
- Ensemble Machine Learning on Bulk RNA-Seq Identifies 17-Gene Signature Predicting Neoadjuvant Chemotherapy Response in Breast Cancer.Current issues in molecular biology · 2026Article
- Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in operable breast cancer patients with hormone receptor-positive, HER2-negative.Frontiers in oncology · 2026Article
- Article
- Evolving incidence patterns for locally advanced operable breast cancer by receptor status: SEER 2010-2021.NPJ breast cancer · 2025Article
- Integration of Gene Expression and Digital Histology to Predict Treatment-Specific Responses in Breast Cancer.medRxiv : the preprint server for health sciences · 2025Article
- Personalized neoadjuvant strategy using 70-gene assay to increase breast-conserving surgery in ER+/HER2- breast cancer.NPJ breast cancer · 2025Article
- Quantitative Biomarkers, Genomic Assays, and Demographics Associated with Breast-Conserving Surgery Following Neoadjuvant Therapy in Early-Stage, Hormone Receptor-Positive, HER-Negative Breast Cancer.Annals of surgical oncology · 2024Article
- ASO Author Reflections: Breast-Conserving Surgery After Neoadjuvant Systemic Therapy for Early-Stage Breast Cancer: Quantitative Biomarkers and Disparities in the Precision-Medicine Era.Annals of surgical oncology · 2024Article
- Predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer using a machine learning approach.Breast cancer research : BCR · 2024Article
- Infrared spectrometry guides cancer treatment.Nature · 2024Article
- The Neoadjuvant Approach to Treatment of Breast Cancer: Multidisciplinary Management to Improve Outcomes.Surgical oncology insight · 2024Article
- Clinical Biomarkers of Tumour Radiosensitivity and Predicting Benefit from Radiotherapy: A Systematic Review.Cancers · 2024Review
- Addressing Social Determinants in the Era of Precision Medicine in Breast Cancer: Is It Sufficient to Reduce Disparities?Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024Article
- Predictive factors for complete pathologic response in luminal breast cancer: impact of ki67 and HER2 low expression.Therapeutic advances in medical oncology · 2024Article
- The Role of the NOLUS Score in Predicting pCR and iDFS in HR-positive HER2-negative Early Breast Cancer Patients who Received Neoadjuvant Chemotherapy.Cancer diagnosis & prognosisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
OncotypeDX and MammaPrint assays have not been validated to predict pathologic complete response (pCR) to neoadjuvant chemotherapy (NACT) in early-stage breast cancer patients. We analyzed the 2010-2019 National Cancer Database and found that high OncotypeDX recurrence scores or high MammaPrint scores were associated with greater odds of pCR. Our findings suggest that OncotypeDX and MammaPrint testing predict pCR after NACT and could facilitate clinical decision-making between clinicians and patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.